Blandine Lacroix is Corporate Vice President, Obesity, at Novo Nordisk Inc. since October 2, 2017, and joined the US Executive Team in April 2019. She is responsible for leading the obesity business and transforming how the world sees, prevents and treats the disease.
Ms. Lacroix is a proven global commercial leader who brings over 20 years of experience in marketing and commercial leadership within the pharmaceutical industry. She joined Novo Nordisk in 2002 in the company’s Australia affiliate. Since that time, she has progressed through roles of escalating responsibility leading global marketing teams, at the company’s headquarters in Denmark and within the US affiliate, across both diabetes and obesity therapeutic areas. Ms. Lacroix led the establishment of the company’s US obesity business as Vice President, Obesity Marketing, in 2013.
Before joining Novo Nordisk, Ms. Lacroix managed marketing projects and teams for several international companies across diverse industries such as technology, health, manufacturing, and education.
Ms. Lacroix was awarded the Princeton YMCA Centennial Award for Healthy Living, which recognizes leaders in environmental wellbeing and sustainability, in 2017.
Ms. Lacroix studied business as an undergraduate at the MBA Institute in Paris, France, and has a Master of International Business from the University of South Carolina.